Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Identification of a novel human BCL-X promoter and exon

Oncogene volume 19, pages 5534–5538 (2000)Cite this article

Abstract

BCL-XL is a key anti-apoptotic BCL-2 family protein that is widely expressed in human cancer cells and is induced in response to diverse survival signals. The translation initiation codon for BCL-XL is located in BCL-X exon II and previous analyses have indicated that BCL-XL RNAs initiate close to the start of exon II or additionally contain a non-coding first exon (exon IA) spliced to exon II. Using 5′ RACE we have now identified a novel BCL-X non-coding exon (exon IB) which is spliced directly to exon II in place of exon IA. Exon IB-containing RNAs encoded BCL-XL and were detected in non-malignant lymphocytes and lymphoma cells from lymph node biopsies and were expressed at significant levels in cell lines derived from ovarian, colon and breast cancers. We identified two TATA-box sequences upstream of exon IB and demonstrated that surrounding genomic sequences contained strong promoter activity in lymphoma cells (approximately 300-fold active relative to controls). We have therefore identified a powerful new BCL-X promoter and a novel exon that contributes to BCL-XL expression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB. . 1993 Cell 74: 597–608.

  • Choi MS, Boise LH, Gottschalk AR, Quintans J, Thompson CB and Klaus GG. . 1995 Eur. J. Immunol. 25: 1352–1357.

  • Datta R, Manome Y, Taneja N, Boise LH, Weichselbaum R, Thompson CB, Slapak CA and Kufe D. . 1995 Cell Growth Differ. 4: 363–370.

  • Fang W, Rivard JJ, Mueller DL and Behrens TW. . 1994 J. Immunol. 153: 4388–4399.

  • Gonzalez-Garcia M, Perez Ballestero R, Ding L, Duan L, Boise LH, Thompson CB and Nunez G. . 1994 Development 120: 3033–3042.

  • Gotteschalk AR, Boise LH, Thompson CB and Quintans J. . 1994 Proc. Natl. Acad. Sci. USA 91: 7350–7354.

  • Grillot DA, Gonzalez-Garcia M, Ekhterae D, Duan L, Inohara N, Ohta S, Seldin MF and Nunez G. . 1997 J. Immunol. 158: 4750–4757.

  • Grillot DA, Merino R and Nunez G. . 1995 J. Exp. Med. 182: 1973–1983.

  • Harigai M, Miyashita T, Hanada M and Reed JC. . 1996 Oncogene 12: 1369–1374.

  • Krajewska M, Moss SF, Krajewski S, Song K, Holt PR and Reed JC. . 1996 Cancer Res. 56: 2422–2427.

  • Lohmann CM, League AA, Clark WS, Lawson D, DeRose PB and Cohen C. . 2000 Cytometry 42: 61–66.

  • Minn AJ, Rudin CM, Boise LH and Thompson CB. . 1995 Blood 86: 1903–1910.

  • Naik P, Karrim J and Hanahan D. . 1996 Genes Dev. 10: 2105–2116.

  • Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB and Recant WM. . 1997 Cancer J. Sci. Am. 3: 230–237.

  • Packham G, White EL, Eischen CM, Yang H, Parganas E, Ihle JN, Grillot DAM, Zambetti GP, Nunez G and Cleveland JL. . 1998 Genes Dev. 12: 2475–2487.

  • Pena JC, Rudin CM and Thompson CB. . 1998 Cancer Res. 58: 2111–2116.

  • Rodeck U, Jost M, DuHadaway J, Kari C, Jensen PJ, Risse B and Ewert DL. . 1997 Proc. Natl. Acad. Sci. USA 94: 5067–5072.

  • Schott AF, Apel IJ, Nunez G and Clarke MF. . 1995 Oncogene 11: 1389–1394.

  • Xerri L, Parc P, Brousset P, Schlaifer D, Hassoun J, Reed JC, Krajewski S and Birnbaum D. . 1996 Br. J. Haematol. 92: 900–906.

Download references

Acknowledgements

We would like to thank Dr Bridgit Wilkins and Jo-Anne Gregory for providing and preparation of primary lymph nodes. This work was supported by the Ludwig Institute for Cancer Research and the Cancer Research Campaign.

Author information

Author notes

  1. Lucy MacCarthy-Morrogh

    Present address: Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St Mary's Hospital, London, W2 1NY, UK

Authors and Affiliations

  1. Ludwig Institute for Cancer Research, Imperial College School of Medicine, St Mary's Campus, Norfolk Place, London, W2 1PG, UK

    Lucy MacCarthy-Morrogh, Matthew Brimmell & Graham Packham

  2. Cancer Sciences Division, CRC Wessex Medical Oncology Unit, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK

    Lynn Wood, Matthew Brimmell, Peter WM Johnson & Graham Packham

Authors
  1. Lucy MacCarthy-Morrogh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynn Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Brimmell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter WM Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Graham Packham
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

MacCarthy-Morrogh, L., Wood, L., Brimmell, M. et al. Identification of a novel human BCL-X promoter and exon. Oncogene 19, 5534–5538 (2000). https://doi.org/10.1038/sj.onc.1203949

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203949

Keywords

This article is cited by

Search

Advanced search

Quick links